

20th October, 2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
BSE Symbol: INNOVACAP
BSE Scrip Code: 544067

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, "G" Block
Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051
NSE Symbol: INNOVACAP

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Recommendation of GMP Compliance Certificate by the State Service of Ukraine on Medicines and Drugs Control

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that inspection of our manufacturing facility located at Khasra No. 11, SIDCO Industrial Complex, Phase-II Ghatti, Kathua, Jammu & Kashmir, India – 184143 ("Jammu Facility") has been successfully completed by The State Service of Ukraine on Medicines and Drugs Control ("SMDC"). Further, their working group on the evaluation of the results of inspections of medicinal product manufacturing sites for Goods Manufacturing Practice (GMP) requirements has proposed the issuance of GMP compliance certificate to our **Jammu Facility**.

It may also be noted that SMDC is a participating authority under **Pharmaceutical Inspection Co-operation Scheme (PIC/S)**. PIC/S certification will play a pivotal role in positioning the newly commissioned Jammu Facility as an international compliant manufacturing site, enhancing its global credibility and facilitating access to regulated markets.

We request you to take the above on record.

Thanking you,

Yours faithfully,
For **Innova Captab Limited**

Neeharika Shukla
Company Secretary and Compliance Officer